Recently, the “Intracranial Aneurysm-Assisted Embolization Stent,” a device of high interest in the neurointerventional field, has been officially approved for market by China’s National Medical Products Administration (NMPA). Utilizing a complex monofilament weaving process, flexible and adjustable design, and high wall apposition, the stent offers a new solution for the interventional treatment of intracranial aneurysms. Its clinical advantages are particularly notable in reducing vascular wall injury, improving aneurysm neck occlusion, and enhancing distal maneuverability. As the provider of full-process clinical trial services for this project, CCRC Medtech leveraged its customized clinical protocol design capabilities for high-risk neurointerventional devices, multi-center collaborative management efficiency, and deep experience in intracranial disease treatment scenarios to drive the product past key clinical validation milestones, accelerating the launch of this innovative device through solid service results.
01 Deepening Focus in the Neurointerventional Sub-segment Building a Full-Cycle Service Barrier
High-risk medical devices used in intracranial surgery require sufficient and standardized clinical data to demonstrate their clinical value and reliability. Accordingly, clinical trial protocols must be specifically designed based on product characteristics, which places extremely high demands on the professionalism and systematic nature of clinical trial services. As one of the earliest CROs in China to focus on clinical research of neurointerventional devices, CCRC Medtech has established a full-cycle service capability covering “early R&D consulting – clinical trial execution – regulatory submission – post-market surveillance.” Core team members possess over 10 years of experience in the neurointerventional field, are familiar with the clinical characteristics of various products such as stent retrievers, embolic materials, and flow diversion devices, and can quickly identify critical risk points during trials. The company has also established long-term collaborations with over 100 hospitals nationwide qualified to perform neurointerventional procedures, enabling rapid matching of high-quality clinical resources based on product needs.
02 Establishing a CRO Service Structure of “Full-Cycle Empowerment + Global Connectivity”
The assistance in obtaining approval for the intracranial aneurysm-assisted embolization stent represents another achievement for CCRC Medtech’s CRO services in the neurointerventional field. Moving forward, CCRC Medtech will continue to deepen its strategic deployment, strengthening cooperation with neurointerventional clinical experts and research institutions both domestically and internationally, and engaging earlier in the R&D phase of innovative devices to provide clients with more forward-looking clinical trial strategies. Simultaneously, leveraging its familiarity with global regulatory systems including NMPA, FDA, and CE, the company will provide comprehensive regulatory submission and clinical research support for the “global expansion” of domestically produced neurointerventional devices, assisting innovative Chinese medical technologies in reaching the global market. A high-quality CRO serves as a vital bridge connecting innovative medical devices with patients in clinical settings. In the future, CCRC Medtech will continue to rely on its professional expertise as the foundation, helping to accelerate the launch of more innovative products in the neurointerventional field, and contributing its efforts to improving the global standard of treatment for cerebrovascular diseases and safeguarding patient health.